---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-012740"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:05:49.131328+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vanda files NDA for tradipitant to treat motion sickness

## Summary
- Vanda disclosed via 8-K that it filed a New Drug Application for tradipitant for motion sickness.
- Announcement made via social media post on X on January 25, 2025, referencing WWII context.
- No approval or timeline provided; filing is a regulatory step toward potential commercialization.

## SEC filing metadata
- accession: 0001193125-25-012740
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312525012740/0001193125-25-012740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312525012740/d869105d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-012740
- JSON: https://secwatch.observer/filing/0001193125-25-012740.json
- Plain text: https://secwatch.observer/filing/0001193125-25-012740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.